Health and Healthcare
As Stent Business Falls Apart, Field Gets More Crowded
Published:
Medtronic (MDT) got the FDA to approve its new drug-coated stent called the Endeavor. The agency did have some concerns about whether the product has long-term risks or whether it is more effective than drug treatments.
Stents, the little metal supports that keep blocked arteries open, have come under whithering criticism in the medical community. The negative press has almost ruined the business for Boston Scientific (BSX) and Johnson & Johnson (JNJ) BSX, which relies heavily on the product has watched its stock fall from $27 in December 2005 to its current level below $15.
The stent companies hoped that if they coated their products with drugs that would prevent clotting where they were installed, it would help. It does not appear to have worked out that way.
This much is for certain. As demand for stents slackens, the number of players in the market is moving up.
Douglas A. McIntyre
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
